COCOON Baseline Characteristics

Opinion
Video

Panelists discuss how the baseline characteristics of patients in the COCOON trial were evenly matched, with slightly more women than men and a significant number of Asian patients, which is typical for EGFR-mutant non–small cell lung cancer.

Video content above is prompted by the following:

Baseline Characteristics of COCOON Study Population

Upon reviewing the baseline characteristics of the study population, both arms appear to be well-balanced overall, with no significant disparities that would affect the interpretation of treatment outcomes.

  • The demographic distribution reflects a slightly higher proportion of female patients than male patients, which is consistent with the known epidemiology of EGFR-mutant non–small cell lung cancer (NSCLC). This subtype of lung cancer is more frequently observed in women.
  • The average age of participants is in the early 60s, aligning with the typical age of diagnosis for EGFR-mutant NSCLC. Additionally, there is a notably high representation of Asian patients, which is expected given the increased prevalence of EGFR mutations among individuals of Asian descent, including both Asian Americans and those residing in Asia.

Overall, the baseline characteristics were consistent with what would be expected in a population with EGFR-mutant NSCLC and there were no surprising findings that would confound or bias the study’s comparative analysis between the treatment arms.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
2 experts in this video
2 experts in this video
Treatment with lorlatinib might be effective regardless of the presence of central nervous system metastases, according to Misako Nagasaka, MD, PhD.
Most central nervous system events with lorlatinib were grade 1 or 2 in the phase 3 CROWN trial.
Treatment with lorlatinib did not increase cardiovascular events among patients with ALK-positive non–small cell lung cancer in the CROWN trial.
At 5 years, 60% of patients who received lorlatinib in the phase 3 CROWN study achieved progression-free survival.
Related Content